NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: SignaBlok, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, received a Notice of Allowance of Key U.S. Patent for novel and first-in-class agents in sepsis and cancer - SignaBlok.com
SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer

 

NewswireToday - /newswire/ - Shrewsbury, MA, United States, 2013/07/01 - SignaBlok, Inc., a Massachusetts-based biopharmaceutical startup, received a Notice of Allowance of Key U.S. Patent for novel and first-in-class agents in sepsis and cancer - SignaBlok.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

SignaBlok, Inc. today announced that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application covering TREM-1 receptor-specific peptides for sepsis, cancer and other inflammation-associated indications. The allowed claims cover both product composition and treatment methods.

This application is the first patent application to issue, which broadly covers the Company's proprietary, first-in-class peptides, known as the SCHOOL peptides. The peptides target TREM-1, a specific receptor that serves as an inflammation amplifier and is critically involved in the pathogenesis of various cancers, sepsis, rheumatoid arthritis, and other inflammation-associated diseases.

"We are pleased that the USPTO has allowed this patent application, which will substantively expand the coverage of SignaBlok's intellectual property estate," said Alexander Sigalov, Ph.D., President, Inventor and Founder of SignaBlok. "SignaBlok continues to develop novel intellectual property in the area of the SCHOOL technology that allows to block specific receptors in a new, ligand-independent manner. We have recently succeeded in the animal proof-of-concept testing of the SCHOOL technology in sepsis and lung cancer. Accordingly, we plan to consolidate key intellectual property required to develop and commercialize first-in-class therapies for these and other serious diseases with unmet clinical needs".

The new patent is expected to issue in the next few months.

About SignaBlok
SignaBlok (signablok.com) is developing a new class of therapies SCHOOL peptides, the innovative modulatory peptides that can be rationally designed for nearly any cell surface receptor and have broad potential to treat and prevent a wide range of serious diseases with unmet clinical needs. SignaBlok is also developing a nanotechnology that enables targeted delivery of SCHOOL peptides and other therapies and/or imaging agents, aiming to improve efficacy, reduce dose, and allow image-guided therapy.

SignaBlok Forward-Looking Statement
Various statements in this release concerning SignaBlok's future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such products. SignaBlok's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although SignaBlok's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by SignaBlok. Readers are cautioned not to rely on these forward-looking statements.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: SignaBlok, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


SignaBlok Announces Notice of Patent Allowance on TREM-1 Peptide Therapeutics for Sepsis and Cancer

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Alexander Sigalov - SignaBlok.com 
203-505-3807 sigalov[.]signablok.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any SignaBlok, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From SignaBlok, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome
Ipsen and IRLAB Enter Exclusive Worldwide Licensing Agreement Aimed to Improve the Lives of People Living with Parkinson’s Disease
Exelixis and Ipsen Announce Cabozantinib in Combination with An Immune Checkpoint Inhibitor Significantly Improved Progression
Ipsen Opts-in to Join Exelixis with Ongoing Development of Cabometyx® for People Living with A Form of Thyroid Cancer
Antibiotic Alternatives Stimulate New Product Development in Global Animal Feed Ingredient Market Finds Frost & Sullivan
Health Tech Company Hologram Sciences Launches Personalized Health & Nutrition Innovation with 0 Million Backing
DSM Acquires Flavor & Fragrance Bio-based Intermediates Business from Amyris
Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo®

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Limelon Advertising, Co.

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2021 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)